HEPATOLOGY

dc.creatorArab, Juan Pablo
dc.creatorKarpen, Saul J
dc.creatorDawson, Paul A
dc.creatorArrese-Jiménez, Marco Antonio
dc.creatorTrauner, Michael
dc.date2021-08-23T22:59:55Z
dc.date2022-07-07T14:57:31Z
dc.date2021-08-23T22:59:55Z
dc.date2022-07-07T14:57:31Z
dc.date2017
dc.date.accessioned2023-08-23T00:21:08Z
dc.date.available2023-08-23T00:21:08Z
dc.identifier1150327
dc.identifier1150327
dc.identifierhttps://hdl.handle.net/10533/252736
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8354802
dc.descriptionNonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing prevalence of this disease and of its aggressive form nonalcoholic steatohepatitis (NASH) will require novel therapeutic approaches to prevent disease progression to advanced fibrosis or cirrhosis and cancer. In recent years, bile acids have emerged as relevant signaling molecules that act at both hepatic and extrahepatic tissues to regulate lipid and carbohydrate metabolic pathways as well as energy homeostasis. Activation or modulation of bile acid receptors, such as the farnesoid X receptor and TGR5, and transporters, such as the ileal apical sodium- dependent bile acid transporter, appear to affect both insulin sensitivity and NAFLD/ NASH pathogenesis at multiple levels, and these approaches hold promise as novel therapies. In the present review, we summarize current available data on the relationships of bile acids to NAFLD and the potential for therapeutically targeting bile- acid- related pathways to address this growing world- wide disease.
dc.descriptionRegular 2015
dc.descriptionFONDECYT
dc.descriptionFONDECYT
dc.languageeng
dc.relationhandle/10533/111557
dc.relationhandle/10533/111541
dc.relationhandle/10533/108045
dc.relationhttps://doi.org/10.1002/hep.28709
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsinfo:eu-repo/semantics/article
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleBile Acids and Nonalcoholic Fatty Liver Disease: Molecular Insights and Therapeutic Perspectives
dc.titleHEPATOLOGY
dc.typeArticulo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución